Compare Adaptive Biotechnologies Corp (ADPT) vs Mongodb Inc (MDB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Mongodb Inc — how do they compare? Adaptive Biotechnologies Corp trades at $20.25 (market cap $3.33B), while Mongodb Inc trades at $355.01 (market cap $29.06B). The key difference: Mongodb Inc is far larger — about 8.7× Adaptive Biotechnologies Corp's market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Mongodb Inc nearer its low. Which is the better fit depends on your goals.
| ADPT | MDB | |
|---|---|---|
Market Cap | $3.33B | $29.06B |
Sector | Health | Technology |
52-Week High | $22.37 | $440.25 |
52-Week Low | $10.24 | $201.08 |
Enterprise Value | $3.19B | $26.66B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
MongoDB (MDB) trades at $361.32, up 1.81% with a bullish technical trend and strong analyst support. Recent earnings beats and revenue growth to $2.01B in 2025 highlight operational momentum, though profitability remains negative. The stock faces overbought signals near-term but benefits from AI-driven demand and raised 2026 guidance.
Outlook is positive with a $399.05 consensus price target, but risks include high valuation multiples, ongoing losses, and legal scrutiny. Investors should weigh robust growth against profitability challenges and market volatility for balanced exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Mongodb Inc
Founded in 2007, MongoDB is a document-oriented database with nearly 33,000 paying customers and well past 1.5 million free users. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.
Read more on MDB →
